{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:47:49Z","timestamp":1782409669808,"version":"3.54.5"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10147-026-03072-5","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T16:18:35Z","timestamp":1779985115000},"page":"1131-1136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of therapeutic strategy changes for patients with melanoma using a national dataset in Japan"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6744-6291","authenticated-orcid":false,"given":"Hiroyuki","family":"Goto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsubasa","family":"Bito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Hiroyasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Ihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiko","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Shintani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Tsuruta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"3072_CR1","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/1346-8138.17086","volume":"51","author":"S Koizumi","year":"2024","unstructured":"Koizumi S, Inozume T, Nakamura Y (2024) Current surgical management for melanoma. J Dermatol 51:312\u2013323","journal-title":"J Dermatol"},{"key":"3072_CR2","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","volume":"17","author":"U Leiter","year":"2016","unstructured":"Leiter U, Stadler R, Mauch C et al (2016) Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol 17:757\u2013767","journal-title":"Lancet Oncol"},{"key":"3072_CR3","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries MB, Thompson JF, Cochran AJ et al (2017) Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 376:2211\u20132222","journal-title":"N Engl J Med"},{"key":"3072_CR4","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1007\/s10147-021-02029-0","volume":"26","author":"D Ogata","year":"2021","unstructured":"Ogata D, Tanese K, Nakamura Y et al (2021) Impact of the changes in the completion lymph node dissection criteria and approval of adjuvant therapies on the real-world outcomes of Japanese stage III melanoma patients. Int J Clin Oncol 26:2338\u20132346","journal-title":"Int J Clin Oncol"},{"key":"3072_CR5","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s13555-022-00712-2","volume":"12","author":"Y Kiyohara","year":"2022","unstructured":"Kiyohara Y, Matsuzaki T, Teng L et al (2022) Drug utilization and medical cost study focusing on moisturizers in cancer patients treated with molecular targeted therapy: A retrospective observational study using data from a Japanese claims database. Dermatol Ther (Heidelb) 12:1041\u20131054","journal-title":"Dermatol Ther (Heidelb)"},{"key":"3072_CR6","doi-asserted-by":"publisher","first-page":"2229465","DOI":"10.1080\/09546634.2023.2229465","volume":"34","author":"C Wang","year":"2023","unstructured":"Wang C, Torisu-Itakura H, Hanada T et al (2023) Treatment persistence of interleukin-17 inhibitor class drugs among patients with psoriasis in Japan: a retrospective database study. J Dermatolog Treat 34:2229465","journal-title":"J Dermatolog Treat"},{"key":"3072_CR7","volume-title":"R: A language and environment for statistical computing","author":"R_Core_Team","year":"2024","unstructured":"R_Core_Team (2024) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria"},{"key":"3072_CR8","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1158\/1078-0432.CCR-22-3145","volume":"29","author":"J Larkin","year":"2023","unstructured":"Larkin J, Del Vecchio M, Mandal\u00e1 M et al (2023) Adjuvant nivolumab versus ipilimumab in resected stage III\/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238. Clin Cancer Res 29:3352\u20133361","journal-title":"Clin Cancer Res"},{"key":"3072_CR9","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","volume":"22","author":"AMM Eggermont","year":"2021","unstructured":"Eggermont AMM, Blank CU, Mandal\u00e0 M et al (2021) Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol 22:643\u2013654","journal-title":"Lancet Oncol"},{"key":"3072_CR10","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","volume":"383","author":"R Dummer","year":"2020","unstructured":"Dummer R, Hauschild A, Santinami M et al (2020) Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med 383:1139\u20131148","journal-title":"N Engl J Med"},{"key":"3072_CR11","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S1470-2045(20)30062-0","volume":"21","author":"R Dummer","year":"2020","unstructured":"Dummer R, Brase JC, Garrett J et al (2020) Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF(V600)-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol 21:358\u2013372","journal-title":"Lancet Oncol"},{"key":"3072_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004417","author":"Z Eroglu","year":"2022","unstructured":"Eroglu Z, Broman KK, Thompson JF et al (2022) Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-004417","journal-title":"J Immunother Cancer"},{"key":"3072_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/jnci\/djq455","volume":"103","author":"Y Xing","year":"2011","unstructured":"Xing Y, Bronstein Y, Ross MI et al (2011) Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst 103:129\u2013142","journal-title":"J Natl Cancer Inst"},{"key":"3072_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.33160\/yam.2021.08.008","volume":"64","author":"H Goto","year":"2021","unstructured":"Goto H, Sugita K, Yamamoto O (2021) Limitation of using ultrasonography after positive sentinel lymph node biopsy in a patient with melanoma in the detection of lymph node metastasis. Yonago Acta Med 64:315\u2013317","journal-title":"Yonago Acta Med"},{"key":"3072_CR15","doi-asserted-by":"publisher","first-page":"941921","DOI":"10.1155\/2012\/941921","volume":"2012","author":"Y Xing","year":"2012","unstructured":"Xing Y, Cromwell KD, Cormier JN (2012) Review of diagnostic imaging modalities for the surveillance of melanoma patients. Dermatol Res Pract 2012:941921","journal-title":"Dermatol Res Pract"},{"key":"3072_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/12034754241293131","volume":"29","author":"B Ma","year":"2025","unstructured":"Ma B, James MT, Chan AW et al (2025) National trends in healthcare expenditures for the management of skin cancer in the United States. J Cutan Med Surg 29:33\u201338","journal-title":"J Cutan Med Surg"},{"key":"3072_CR17","doi-asserted-by":"publisher","first-page":"100320","DOI":"10.1016\/j.esmoop.2021.100320","volume":"6","author":"MG Franken","year":"2021","unstructured":"Franken MG, Leeneman B, Aarts MJB et al (2021) Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs. ESMO Open 6:100320","journal-title":"ESMO Open"},{"key":"3072_CR18","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1002\/cncr.33515","volume":"127","author":"KC Gogebakan","year":"2021","unstructured":"Gogebakan KC, Mukherjee K, Berry EG et al (2021) Impact of novel systemic therapies on the first-year costs of care for melanoma among Medicare beneficiaries. Cancer 127:2926\u20132933","journal-title":"Cancer"},{"key":"3072_CR19","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/jamadermatol.2023.3179","volume":"159","author":"SB Bateni","year":"2023","unstructured":"Bateni SB, Nguyen P, Eskander A et al (2023) Changes in health care costs, survival, and time toxicity in the era of immunotherapy and targeted systemic therapy for melanoma. JAMA Dermatol 159:1195\u20131204","journal-title":"JAMA Dermatol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03072-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03072-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03072-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:19:26Z","timestamp":1782407966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03072-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3072"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03072-5","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}